Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neurology"
DOI: 10.1007/s00415-017-8410-6
Abstract: Intravenous tissue plasminogen activator (tPA) thrombolysis remains the only proven pharmacological treatment for acute ischemic stroke [1]. A common clinical scenario is where a patient with atrial fibrillation (AF) on therapeutic anticoagulation presents with an… read more here.
Keywords: thrombolysis; reversal idarucizumab; dabigatran reversal; stroke thrombolysis ... See more keywords
Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort
Sign Up to like & getrecommendations! Published in 2020 at "Neurology"
DOI: 10.1212/wnl.0000000000009155
Abstract: Objective To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of thrombolyzed… read more here.
Keywords: dabigatran reversal; reversal idarucizumab; idarucizumab; thrombolyzed patients ... See more keywords
Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort
Sign Up to like & getrecommendations! Published in 2021 at "Neurology"
DOI: 10.1212/wnl.0000000000009542
Abstract: In the article “Stroke Reperfusion Therapy Following Dabigatran Reversal With Idarucizumab in a National Cohort” by Barber et al.,1 the first sentence in the Methods section should denote this study as providing Class III evidence.… read more here.
Keywords: therapy following; dabigatran reversal; reperfusion therapy; reversal idarucizumab ... See more keywords